UroGen Pharma (URGN) Stock Forecast & Price Target

UroGen Pharma is viewed favorably because its commercial launch of ZUSDURI is scaling rapidly, with 2Q26 net sales of $50.4M, 73% quarter-over-quarter growth, 1,444 activated sites, and repeat prescribers rising to about 45%, signaling strong physician adoption and durable demand. Its profitability profile is also improving, as 2Q26 revenue reached $72.5M versus $56.9M expected and net loss narrowed to $0.28 per share, while $108M of cash and equivalents was reported at the midpoint of 2026. The outlook is further supported by intellectual property and pipeline depth, including the Teva settlement preserving JELMYTO protection to 2030, UGN-103’s 94.5% six-month DOR, and UGN-104 and UGN-501 programs that could extend franchise exclusivity and expand the addressable market.

UroGen Pharma is a company whose long-term value is heavily dependent on sustaining exclusivity and commercial adoption of Jelmyto and Zusduri, yet its own outlook still assumes gradual sales erosion starting in the early 2030s, which highlights how fragile the revenue base may be. Although a new U.S. patent could protect methods for treating recurrent LG-IR-NMIBC into July 2044, that upside is not yet reflected in forecasts, and the core risk remains that the company may fail to transition successfully to UGN-103 and UGN-104 or defend share against competition and discounting. With a DCF-derived rNPV of $4.26B and firm value of $4.2B as of mid-2027, the bearish view is reinforced by dilution risk, regulatory and clinical setbacks, and uncertainty around realizing projected sales from its U.S.-centered product revenue.